Stockscreener 앱 받기
6.74
19.93%
1.12
시간 외 거래:
6.66
-0.08
-1.19%
전일 마감가:
$5.62
열려 있는:
$5.6
하루 거래량:
3.89M
Relative Volume:
1.62
시가총액:
$370.36M
수익:
$3.64M
순이익/손실:
$-87.37M
주가수익비율:
-1.6399
EPS:
-4.11
순현금흐름:
$-86.46M
1주 성능:
+10.86%
1개월 성능:
+43.10%
6개월 성능:
+16.41%
1년 성능:
+200.89%
1일 변동 폭
$5.59
$6.88
1주일 범위
$5.43
$6.88
52주 변동 폭
$2.24
$9.10
Verastem Inc Stock (VSTM) Company Profile
명칭
Verastem Inc
전화
(781) 292-4200
주소
117 KENDRICK STREET, NEEDHAM, MA
VSTM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
6.74 | 314.31M | 3.64M | -87.37M | -86.46M | -4.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-10 | 개시 | Jefferies | Buy |
| 2025-03-24 | 재확인 | H.C. Wainwright | Buy |
| 2024-12-31 | 재확인 | BTIG Research | Buy |
| 2024-09-30 | 개시 | Guggenheim | Buy |
| 2023-11-21 | 재개 | BTIG Research | Buy |
| 2023-09-27 | 개시 | B. Riley Securities | Buy |
| 2023-06-15 | 업그레이드 | Mizuho | Neutral → Buy |
| 2022-09-07 | 재개 | Alliance Global Partners | Buy |
| 2022-04-29 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-04-14 | 개시 | RBC Capital Mkts | Outperform |
| 2022-03-09 | 개시 | Truist | Buy |
| 2021-07-01 | 개시 | Alliance Global Partners | Buy |
| 2021-05-24 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2019-06-20 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2019-05-10 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-07-13 | 개시 | BTIG Research | Buy |
| 2018-05-02 | 개시 | Seaport Global Securities | Buy |
| 2018-03-08 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-09-07 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-13 | 개시 | Oppenheimer | Outperform |
| 2017-03-24 | 재확인 | H.C. Wainwright | Buy |
| 2015-09-29 | 다운그레이드 | Cantor Fitzgerald | Buy → Hold |
| 2015-09-29 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2015-09-29 | 다운그레이드 | Jefferies | Buy → Hold |
| 2015-09-29 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2015-09-28 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2015-09-28 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2015-09-09 | 개시 | Raymond James | Strong Buy |
| 2015-05-12 | 재확인 | UBS | Buy |
| 2015-04-08 | 개시 | H.C. Wainwright | Buy |
| 2015-01-23 | 재확인 | ROTH Capital | Buy |
| 2014-07-08 | 재개 | Oppenheimer | Perform |
| 2014-02-11 | 개시 | Mizuho | Buy |
모두보기
Verastem Inc 주식(VSTM)의 최신 뉴스
Verastem (VSTM.O) Surges 19.9% on KDJ Golden Cross and Mysterious Order Flow - AInvest
Verastem Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Verastem (VSTM.O) Surges 19.9%: What’s Behind the Sharp Intraday Move? - AInvest
Using Python tools to backtest Verastem Inc. strategiesAI Trend Detection for Entry Timing - Newser
What makes Verastem Inc. stock price move sharplyMassive ROI Stock Selections - thegnnews.com
Verastem's (VSTM) Breakthrough in KRAS-Driven Cancers and Commercialization Momentum - AInvest
Transcript : Verastem, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Verastem stock climbs on Q2 beat (VSTM:NASDAQ) - Seeking Alpha
Verastem’s Promising Phase 3 Study in Ovarian Cancer: A Potential Game-Changer? - TipRanks
RBC Raises Price Target on Verastem to $13 From $12, Keeps Outperform, Speculative Risk - MarketScreener
Verastem Inc files for mixed shelf offering of up to $300 millionSEC filing - MarketScreener
Earnings call transcript: Verastem Q2 2025 sees revenue growth and FDA approval - Investing.com
Verastem’s Promising Market Expansion and Financial Health Drive Buy Rating - TipRanks
Verastem: Q2 Earnings Snapshot - Connecticut Post
Verastem Q2 2025 Earnings Call Transcript - MarketBeat
Verastem Inc (VSTM) Q2 2025 Earnings Call Highlights: FDA Approval and Strong Launch Drive ... By GuruFocus - Investing.com Canada
Verastem Oncology’s Q2 2025 Financial and Business Highlights - TipRanks
Verastem Inc (VSTM) Q2 2025 Earnings Call Highlights: FDA Approval and Strong Launch Drive Positive Momentum - GuruFocus
Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates - BioSpace
Verastem 2025 Q2 Earnings Deepened Losses Amid Product Launch - AInvest
Verastem Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Custom strategy builders for tracking Verastem Inc.Free Short Term Buy List With Stop Protection - Newser
Verastem Oncology Gambles On Cancer Drug Launch Despite Deepening Losses - Finimize
Verastem (VSTM) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Verastem's Q2 2025 Earnings and Pipeline Progress: A Deep Dive into R&D Momentum and Long-Term Value Creation - AInvest
Biopharma firm Verastem Oncology Q2 net loss widens - MarketScreener
Verastem reports Q2 EPS (39c) vs. (31c) last year - TipRanks
Verastem CEO Paterson sells $7,738 in shares By Investing.com - Investing.com South Africa
Verastem CEO Paterson sells $7,738 in shares - Investing.com
Will Verastem Inc. continue its uptrendIntelligent Trade Forecast With AI Analytics - Newser
Intrinsic Value of Verastem Inc. Stock: Is It Undervalued or OvervaluedTechnical Trend Forecast for Investors - Newser
Best data tools to analyze Verastem Inc. stockTrading Watchlist with Real Time Filters - Newser
Visual trend scoring systems applied to Verastem Inc.Free Pattern Alert With ROI Driven Strategy - Newser
Leading vs lagging indicators on Verastem Inc. performanceFree News Based Entry Opportunity Alerts - Newser
Verastem VSTM Q2 2025 Earnings Preview Upside Potential on Strong Revenue Growth - AInvest
Jefferies Financial Group Inc. Makes New $1.63 Million Investment in Verastem, Inc. (NASDAQ:VSTM) - Defense World
Does Verastem Inc. stock perform well during market downturnsUnlock powerful market trend analysis - Jammu Links News
What markets is Verastem Inc. expanding into Is TROO stock a good long term investment option - Jammu Links News
How strong is Verastem Inc. company’s balance sheetHigh-yield market plays - Jammu Links News
Is Verastem Inc. stock overvalued or undervaluedInvest confidently with advanced analysis tools - Jammu Links News
How does Verastem Inc. compare to its industry peersAchieve breakthrough gains with expert advice - Jammu Links News
Should I hold or sell Verastem Inc. stock in 2025Maximize gains with expert analysis - Jammu Links News
What is Verastem Inc. company’s growth strategyUnstoppable profit momentum - Jammu Links News
What institutional investors are buying Verastem Inc. stockBuild a diversified portfolio for risk mitigation - Jammu Links News
What drives Verastem Inc. stock priceOutperformance with explosive growth - Jammu Links News
What analysts say about Verastem Inc. stockFree Consultation - Jammu Links News
When is Verastem Inc. stock expected to show significant growthMarket-crushing stock picks - Jammu Links News
Verastem, Inc. (NASDAQ:VSTM) Sees Large Growth in Short Interest - Defense World
Why Verastem Inc. stock attracts strong analyst attentionBuy Signal Based on Chart Analysis Confirmed - beatles.ru
Is Verastem Inc. reversing from oversold territoryWeekly Signal Report with Trend Summary - Newser
Verastem Inc (VSTM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):